Fawad Khan, MD
Clinical Neurophysiology · New Orleans, LANPI 1699978122
Payments from drug & device makers
Across 931 payments — averaging $760.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$118K
- Pfizer$84K
- Biohaven Pharmaceutical Holding Company Ltd.$73K
- Immedica Pharma US, Inc.$69K
- Amgen$60K
- Lilly USA, LLC$48K
- plus $257K from 25 others
What the payments were for
- Consulting fees$85,61718%
- Speaking & faculty fees$346,19371%
- Grants$440%
- Travel & lodging$36,0257%
- Food & beverage$20,2874%
- Education$920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 239 | $117,574 |
| Pfizer | 46 | $83,509 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $73,121 |
| Immedica Pharma US, Inc. | 19 | $68,976 |
| Amgen | 92 | $59,657 |
| Lilly USA, LLC | 74 | $48,423 |
| SK Life Science, Inc. | 58 | $46,396 |
| Teva Pharmaceuticals USA, Inc. | 58 | $45,771 |
| Lundbeck LLC | 60 | $39,988 |
| UCB, Inc. | 103 | $33,950 |
| Impel Pharmaceuticals Inc. | 21 | $28,684 |
| UCB SA | 3 | $19,113 |
| Neurelis, Inc. | 33 | $16,280 |
| H. Lundbeck A S | 2 | $8,485 |
| Eisai Inc. | 16 | $8,381 |
| Livanova USA, Inc. | 11 | $3,044 |
| DIXI Medical USA Corp | 2 | $1,685 |
| Neuropace, Inc. | 8 | $1,608 |
| Natus Medical Incorporated | 1 | $1,000 |
| Zimmer Biomet | 3 | $920 |
| Jazz Pharmaceuticals Inc. | 25 | $496 |
| Biohaven Pharmaceuticals, Inc. | 7 | $288 |
| Sunovion Pharmaceuticals Inc. | 19 | $227 |
| Greenwich Biosciences, Inc. | 5 | $158 |
| Novartis | 2 | $99 |
| Biogen | 1 | $97 |
| Merck | 2 | $42 |
| Johnson & Johnson | 1 | $38 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$66,676
- AIMOVIG$58,532
- BOTOX$45,825
- VYEPTI$38,801
- ZAVZPRET$37,215
- QULIPTA$36,147
- XCOPRI$33,572
- EMGALITY$28,563
- Trudhesa$28,368
- AJOVY$20,967
- REYVOW$16,975
- VALTOCO$15,664
- Nayzilam$15,661
- Briviact$11,625
- Cenobamate$11,323
- NURTEC ODT$5,671
- Fintepla$4,492
- VNS Therapy$1,609
- RNS Neurostimulator Kit$1,466
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,238
How this compares
Too few clinical neurophysiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnfiClobazam | 20 | $147,164 |
| AptiomEslicarbazepine Acetate | 34 | $91,610 |
| BriviactBrivaracetam | 50 | $87,690 |
| Aimovig AutoinjectorErenumab-Aooe | 85 | $73,495 |
| Emgality PenGalcanezumab-Gnlm | 81 | $58,722 |
| UbrelvyUbrogepant | 50 | $40,791 |
| FycompaPerampanel | 31 | $36,154 |
| Ajovy SyringeFremanezumab-Vfrm | 30 | $25,465 |
| Nurtec OdtRimegepant Sulfate | 18 | $23,840 |
| QuliptaAtogepant | 12 | $23,780 |
| Clobazam | 102 | $23,103 |
| NayzilamMidazolam | 25 | $22,042 |
| Lacosamide | 217 | $18,099 |
| Rufinamide | 19 | $14,147 |
| Lamotrigine ErLamotrigine | 20 | $5,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lundbeck LLCOnfi | $39,988 | $147,16420 claims |
| UCB, Inc.Briviact, Nayzilam | $33,950 | $109,73275 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $227 | $91,61034 claims |
| AbbVieUbrelvy, Qulipta | $117,574 | $64,57162 claims |
| Eisai Inc.Fycompa | $8,381 | $36,15431 claims |
| PfizerNurtec Odt | $83,509 | $23,84018 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $1,16178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in New Orleans
- Jeffrey NichollNew Orleans$58
- Cornel RogersGretna$13K
- Arpitha KomaragiriShreveport$3K
- James DomingueLafayette$2K
- Cheryl RinconKenner$557
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.